计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
JNJ-7706621是CDK和Aurora的一个双重抑制剂,在体外可以有效地抑制CDK1、CDK2、CDK3、CDK4、CDK6、Aurora A和Aurora B,对应的IC50值分别为0.009、0.004、0.003、0.058、0.253、0.175、0.011和0.015 μmol/L。JNJ-7706621选择性地抑制正常人细胞和不同类型的肿瘤细胞的增殖,JNJ-7706621对肿瘤细胞(IC50值0.112 - 0.514μmol/L)的作用是正常细胞(IC50值3.67 - 5.42μmol/L)的10倍。在人癌细胞中,不管p53、视网膜母细胞瘤或p-糖蛋白状态如何,JNJ-7706621都可以诱导细胞凋亡、抑制集落形成和细胞生长。
Information
JNJ-7706621 is pan-CDKinhibitor with the highest potency on CDK1/2 withIC50of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
In vitro
JNJ-7706621 also shows some inhibition to VEGF-R2, FGF-R2, and GSK3β, with IC50 of 154-254 nM. JNJ-7706621 shows inhibitory effect on a panel of human cancer cell types, including HeLa, HCT-116, SK-OV-3, PC3, DU145, A375, MDA-MB-231, MES-SA, and MES-SA/Dx5, with IC50 of 112-514 nM, independent of p53, retinoblastoma, or P-glycoprotein status. JNJ-7706621 is several-fold less potent at inhibiting growth of normal cell types, including MRC-5, HASMC, HUVEC, and HMVEC, with IC50 of 3.67-5.42 μM. In HeLa or U937 cells, JNJ-7706621 (0.5-3 μM) delays exit from G1, arrests cells in G2-M, induces endoreduplication, activates apoptosis, and reduces colony formation. In a HeLa cell line, incremental treatment with increasing concentrations of JNJ-7706621 leads to a 16-fold resistance, which may be mediated by ABCG2.
In vivo
In mouse xenograft model of A375 melanoma human tumor, JNJ-7706621 (100 or 125 mg/kg) causes tumor regression.
Cell Data
cell lines:HepG2 Ntcp and Huh7-Ntcp cells
Concentrations:1 nM - 10 μM, dissolved in DMSO
Incubation Time:48 hours
Powder Purity:≥97%
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | J408880 |